-
1.发明授权Spirohydantoin compounds and methods for the modulation of chemokine receptor activity 失效螺乙内酰脲化合物和调节趋化因子受体活性的方法公开(公告)号：US07351713B2
公开(公告)日：2008-04-01
申请号：US10937878
申请日：2004-09-10
申请人： Laval Chan Chun Kong , Ming-Qiang Zhang , Christophe Moinet , Marc Courchesne , Thumkunta Jagadeeswar Reddy , Melanie Proulx
发明人： Laval Chan Chun Kong , Ming-Qiang Zhang , Christophe Moinet , Marc Courchesne , Thumkunta Jagadeeswar Reddy , Melanie Proulx
IPC分类号： A61K31/438 , C07D471/10
CPC分类号： C07D471/10
摘要： Compounds of formula I wherein R1, R2, R3, R4 and R5 are as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
摘要翻译： 其中R 1，R 2，R 3，R 4和R 5的式I化合物 本文定义的或其药学上可接受的盐，水合物或溶剂化物可用于调节CCR5趋化因子受体活性。
-
2.发明授权Spiro compounds and methods for the modulation of chemokine receptor activity 失效Spiro化合物和调节趋化因子受体活性的方法公开(公告)号：US07288548B2
公开(公告)日：2007-10-30
申请号：US10937880
申请日：2004-09-10
申请人： Laval Chan Chun Kong , Ming-Qiang Zhang , Christophe Moinet , Marc Courchesne , Thumkunta Jagadeeswar Reddy
发明人： Laval Chan Chun Kong , Ming-Qiang Zhang , Christophe Moinet , Marc Courchesne , Thumkunta Jagadeeswar Reddy
IPC分类号： A61K31/438 , C07D471/10
CPC分类号： C07D471/10
摘要： Compounds of formula I wherein X, Y, Z, W, R1 and R2 as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
摘要翻译： 其中本文定义的X，Y，Z，W，R 1和R 2的式I化合物或其药学上可接受的盐，水合物或溶剂合物可用于 调节CCR5趋化因子受体活性。
-
3.发明申请Spirohydantoin compounds and methods for the modulation of chemokine receptor activity 失效螺乙内酰脲化合物和调节趋化因子受体活性的方法公开(公告)号：US20050075360A1
公开(公告)日：2005-04-07
申请号：US10937878
申请日：2004-09-10
申请人： Laval Chan Chun Kong , Ming-Qiang Zhang , Christophe Moinet , Marc Courchesne , Thumkunta Reddy , Melanie Proulx
发明人： Laval Chan Chun Kong , Ming-Qiang Zhang , Christophe Moinet , Marc Courchesne , Thumkunta Reddy , Melanie Proulx
IPC分类号： C07D471/10 , A61K31/4747
CPC分类号： C07D471/10
摘要： Compounds of formula I wherein R1, R2, R3, R4 and R5 are as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
摘要翻译： 其中R 1，R 2，R 3，R 4和R 5如本文所定义的式I化合物或其药学上可接受的盐，水合物或溶剂合物可用于调节CCR5趋化因子受体活性。
-
公开(公告)号：US08124613B2
公开(公告)日：2012-02-28
申请号：US12304685
申请日：2007-06-14
申请人： Christophe Moinet , Charles Blais , Monica Bubenik , Laval Chan Chun Kong , Marc Courchesne , Oswy Z. Pereira , Réal Denis , Louis Vaillancourt , Constantin G. Yannopoulos
发明人： Christophe Moinet , Charles Blais , Monica Bubenik , Laval Chan Chun Kong , Marc Courchesne , Oswy Z. Pereira , Réal Denis , Louis Vaillancourt , Constantin G. Yannopoulos
IPC分类号： A61K31/44 , C07D401/00
CPC分类号： C07D471/20
摘要： Compounds according to formula (I): wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R′1, and R′2 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.
摘要翻译： 根据式（I）的化合物：其中R 1，R 2，R 3，n和X如本文所定义，其药学上可接受的盐，水合物和溶剂合物可用于调节CCR5趋化因子受体活性。 另外，根据式III的化合物：其中Z，R'1和R'2如本文所定义，其药学上可接受的盐，水合物和溶剂合物可用作产生调节CCR5趋化因子受体活性的化合物的中间体 。
-
公开(公告)号：US20110105546A1
公开(公告)日：2011-05-05
申请号：US12304685
申请日：2007-06-14
申请人： Christophe Moinet , Charles Blas , Monica Bubenik , Laval Chan Chun Kong , Marc Courchesne , Oswy Pereira , Réal Denis , Louis Vaillancourt , Constantin Yannopoulos
发明人： Christophe Moinet , Charles Blas , Monica Bubenik , Laval Chan Chun Kong , Marc Courchesne , Oswy Pereira , Réal Denis , Louis Vaillancourt , Constantin Yannopoulos
IPC分类号： A61K31/46 , C07D451/00 , A61P31/18 , A61P29/00
CPC分类号： C07D471/20
摘要： Compounds according to formula (I): wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R′1, and R′2 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.
摘要翻译： 根据式（I）的化合物：其中R 1，R 2，R 3，n和X如本文所定义，其药学上可接受的盐，水合物和溶剂合物可用于调节CCR5趋化因子受体活性。 另外，根据式III的化合物：其中Z，R'1和R'2如本文所定义，其药学上可接受的盐，水合物和溶剂合物可用作产生调节CCR5趋化因子受体活性的化合物的中间体 。
-
6.发明申请Novel Spirotropane Compounds and Methods for the Modulation of Chemokine Receptor Activity 失效新型Spirotropane化合物和调节趋化因子受体活性的方法公开(公告)号：US20080267906A1
公开(公告)日：2008-10-30
申请号：US11792581
申请日：2005-12-09
申请人： Laval Chan Chun Kong , Christophe Moinet , Marc Courchesne , Louis Vaillancourt , Charles Blais , Monica Bubenik
发明人： Laval Chan Chun Kong , Christophe Moinet , Marc Courchesne , Louis Vaillancourt , Charles Blais , Monica Bubenik
IPC分类号： A61K38/20 , C07D487/22 , A61P31/18 , A61P29/00 , A61K31/439
CPC分类号： C07D451/02
摘要： Compounds according to formula (I): wherein A, R1, R2 and R3 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.
摘要翻译： 根据式（I）的化合物：其中A，R 1，R 2和R 3 3定义如本文所定义，并且药学上可接受的 其盐，水合物和溶剂合物可用于调节CCR5趋化因子受体活性。
-
7.发明申请Spiro compounds and methods for the modulation of chemokine receptor activity 审中-公开Spiro化合物和调节趋化因子受体活性的方法公开(公告)号：US20050075326A1
公开(公告)日：2005-04-07
申请号：US10893583
申请日：2004-07-19
申请人： Laval Chan Chun Kong , Ming Zhang , Christophe Moinet , Melanie Proulx , Thumkunta Reddy , Marc Courchesne
发明人： Laval Chan Chun Kong , Ming Zhang , Christophe Moinet , Melanie Proulx , Thumkunta Reddy , Marc Courchesne
IPC分类号： A61P31/18 , C07D471/10 , A61K31/55 , A61K31/4747 , C07D487/10
CPC分类号： C07D471/10
摘要： Novel compounds represented by formula I: wherein Y, Z, X, W, R1, R2 and R3 are as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity and the treatment or prevention of diseases associated therewith.
摘要翻译： 由式I表示的新型化合物：其中Y，Z，X，W，R 1，R 2和R 3如本文所定义，或其药学上可接受的盐，水合物或溶剂化物，可用于调节CCR5趋化因子受体活性和治疗或 预防与之相关的疾病。
-
公开(公告)号：US08431556B2
公开(公告)日：2013-04-30
申请号：US12830294
申请日：2010-07-03
CPC分类号： C07J63/008
摘要： The invention relates to 21-keto triterpene compounds of formula (I):wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
摘要翻译： 本发明涉及式（I）的21-酮三萜化合物：其中R1，X和Y如本文所定义，及其药学上可接受的盐和溶剂化物。 这些化合物显示出显着的抗HIV活性。 因此，本发明还涉及通过向需要这种治疗的受试者施用治疗有效量的式（I）化合物或其药学上可接受的盐或溶剂合物来预防或治疗HIV感染的方法。
-
9.发明申请公开(公告)号：US20110077228A1
公开(公告)日：2011-03-31
申请号：US12830294
申请日：2010-07-03
CPC分类号： C07J63/008
摘要： The invention relates to 21-keto triterpene compounds of formula (I):wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof to a subject in need of such treatment.
摘要翻译： 本发明涉及式（I）的21-酮三萜化合物：其中R1，X和Y如本文所定义，及其药学上可接受的盐和溶剂化物。 这些化合物显示出显着的抗HIV活性。 因此，本发明还涉及通过向需要这种治疗的受试者施用治疗有效量的式（I）化合物或其药学上可接受的盐或溶剂合物来预防或治疗HIV感染的方法。
-
10.发明授权Spirotropane compounds and methods for the modulation of chemokine receptor activity 失效Spirotropane化合物和调节趋化因子受体活性的方法公开(公告)号：US08076349B2
公开(公告)日：2011-12-13
申请号：US11792577
申请日：2005-12-09
申请人： Laval Chan Chun Kong , Christophe Moinet , Marc Courchesne , Louis Vaillancourt , Monica Bubenik
发明人： Laval Chan Chun Kong , Christophe Moinet , Marc Courchesne , Louis Vaillancourt , Monica Bubenik
IPC分类号： A61K31/439 , A61K31/4709 , C07D471/18
CPC分类号： C07D451/02
摘要： Compounds according to formula (I): wherein A, R1 and R2 are as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof are useful for the modulation of CCR5 chemokine receptor activity.
摘要翻译： 根据式（I）的化合物：其中A，R 1和R 2如本文所定义，并且其药学上可接受的盐，水合物和溶剂合物可用于调节CCR5趋化因子受体活性。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.035 秒)
